S-3180 : Still Just a Bill


Responsibility in Drug Advertising Act of 2020

This bill prohibits direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.

Action Timeline

Action DateTypeTextSource
2020-01-09IntroReferralRead twice and referred to the Committee on Health, Education, Labor, and Pensions.Senate
2020-01-09IntroReferralIntroduced in SenateLibrary of Congress

Sponsor :

Angus S. King Jr. [I] (ME)
See Cosponsors

Policy Area :

Health
Related Subjects
  • Drug safety, medical device, and laboratory regulation
  • Marketing and advertising
  • Prescription drugs
Related Geographic Entities
Related Organizations

Related Bills

See Related Bills